Therapies for Down Syndrome Regression Disorder
A legfontosabb adatok
- Ki végzi
- University of Colorado, Denver
- Hol
- Aurora és Los Angeles (Egyesült Államok)Mind a 2 helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 2. fázis
- Résztvevők
- 66 fő vett részt
- Kezdés
- 2023. jún. 29.
- Befejezés
- 2026. máj. 28.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoport
- A vizsgált kezelések
- Lorazepam
- Intravenous immunoglobulin (IVIG)
- Tofacitinib
- A regiszteradat frissítve
- 2026. szeptember 3.
Ki vehet részt
- Életkor
- 8 év – 30 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 41 feltétel megnézéseKevesebb
Ki vehet részt
- Individuals with DS between the ages of 8 and 30 years, inclusive. DS is broadly defined to include complete trisomy 21, Robertsonian translocation trisomy 21, partial trisomy 21 (segmental duplication), and mosaic trisomy 21
- Diagnosis of possible or probable DSRD per 2022 consensus guidelines
- Must agree to random treatment assignment
- Must agree to complete a washout of any medications intended to treat symptoms of DSRD or that may interfere with study interventions
- Must be able to present with a study partner or legal guardian at all study visits
Ki nem vehet részt
- Moyamoya syndrome or stroke (active or prior)
- IgA deficiency with antibodies against IgA
- Use of electroconvulsive therapy, lorazepam, or a JAK inhibitor within the last 4 weeks
- Use of immunosuppressant drugs (e.g., prednisone, mycophenolate mofetil, azathioprine) within the last 8 weeks
- Use of strong CP3A4 inhibitors or inducers (e.g., ketoconazole, rifampin) within the last 4 weeks
- Use of moderate CP3A4 inhibitors with a strong CYP2C19 inhibitor (e.g., fluconazole) within the last 4 weeks
- Use of moderate CYP2C9 inhibitors (e.g., valproic acid) within the last 4 weeks
- Use of strong CYP1A2 inducers (e.g., phenobarbital) or moderate CYP1A2 inhibitors (e.g., fluvoxamine) within the last 4 weeks
- Any prior use of methotrexate, cyclophosphamide, or other chemotherapeutics
- Any prior solid organ transplant
- Any prior neurosurgical intervention
- Any subject who has received blood or plasma products ≤ 30 days prior to first Baseline visit
- Known allergies, hypersensitivity, or intolerance to lorazepam, IVIG, or tofacitinib
- Participants may be excluded for other unforeseen reasons or confounding reasons for DSRD symptoms at the study doctor's discretion; Co-occurring Conditions
- Any co-occurring genetic disorder
- Active symptomatic cardiac disease
- Clinically significant chronic or active viral infection, including but not limited to HIV, hepatitis, CMV, EBV, HSV or untreated tuberculosis
- Untreated chronic or active bacterial infection
- History of disseminated herpes zoster, disseminated herpes simplex, or recurrent localized dermatomal herpes zoster
- History of malignancy (solid tumor or leukemia)
- History of acute narrow-angle glaucoma
- History of venous or arterial thrombosis
- Pathogenic neuronal autoantibody positivity against established causes of autoimmune encephalopathy in CSF
- Any subject with a history of anaphylaxis or a severe systemic response to blood or plasma-derived products; Medications or Interventions
- Baseline abnormal renal function indicative of moderate or severe renal disease by eGFR <=45
- General
- Weight less than 40 kg
- Pregnant or breast feeding
- Past or current tobacco smoking
- Poor venous access not allowing repeated blood tests or non-compliance with venipuncture requirements
- Untreated hypothyroidism or hyperthyroidism
- Any vaccination planned during the study or within the last 6 weeks
- Use of IVIG within the last 8 weeks
- Use of rituximab within the past 6 months, unless B cell levels have recovered and are above 50 cells/uL
- Use of other immunosuppressant biologics (e.g., adalimumab, etanercept) within the past 6 months
- Use of certain mood stabilizers or anticonvulsants (e.g., clonazepam, lithium, oxcarbazepine) within the last 4 weeks
Helyszínek itt: Egyesült Államok
- Children's Hospital ColoradoAurora, Egyesült Államok
- Children's Hospital Los AngelesLos Angeles, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
Individuals with Down syndrome (DS) have an increased risk of numerous co-occurring conditions, including the neuropsychiatric condition known as Down Syndrome Regression Disorder (DSRD). A DSRD diagnosis often includes a sub-acute onset of catatonia, mutism, depersonalization, loss of ability to perform activities of daily living, hallucinations, delusions, and aggression and is most commonly observed in adolescents and young adults.
A teljes eredeti leírásKevesebb
The study evaluates the safety and efficacy of three currently prescribed therapies: lorazepam, intravenous immunoglobulin (IVIG) and tofacitinib.
A vizsgálat 3 csoportja
- LorazepamA vizsgált kezelés
Participants will receive lorazepam as an oral pill three times daily for 12 weeks as well as titration doses for an additional 4 weeks (approximately).
- Intravenous immunoglobulin (IVIG)A vizsgált kezelés
Participants will receive 4 doses of IVIG treatment over 12 weeks.
- TofacitinibA vizsgált kezelés
Tofacitinib will be administered as an oral pill at 5 mg twice daily over the 12-week study.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Mechanistic Investigation of Therapies for Down Syndrome Regression Disorder
- A regiszteradat frissítve
- 2026. szeptember 3.